

Nephrogenic Systemic Fibrosis (NSF)

Scleroderma-like fibrosis of skin and other organs, days to months after gadolinium exposure in patients with CKD or ESRD

Skin biopsy

Early PT to prevent contractures, renal transplant

Weigh benefit vs. risk of contrast study

If eGFR < 30, discuss alternate contrast (ferumoxytol) with radiology

Engage patient in shared decisionmaking

Risk of NSF

 \downarrow overall rate (< 0.5%)

↑ in Group I gadolinium agents

 \uparrow if eGFR < 30

ACR Committee of Drugs and Contrast Media. American College of Radiology Manual on Contrast Media. 2021.

Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Kidney Medicine. 2021 Jan 1;3(1):142-50.

